Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Once Weekly Nimacimab Injection, Compared to Placebo Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection in Participants Who Are Overweight or Obese

Next Previous
X
Search
Trial Profile

A Phase 2 Study of Once Weekly Nimacimab Injection, Compared to Placebo Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection in Participants Who Are Overweight or Obese

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimacimab (Primary) ; Semaglutide (Primary)
  • Indications Metabolic disorders; Obesity
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CBeyond
  • Sponsors Skye Bioscience

    • Most Recent Events

    • 13 Jan 2025 According to a Skye Bioscience media release, company anticipates completion of enrollment, 50% enrollment of planned 120 patients after 26 weeks of treatment. Topline weight loss data targeted after full enrollment of 120 patients completing 26 weeks of treatment.
    • 14 Nov 2024 According to a Skye Bioscience media release, company has achieved more than 50% of targeted patient enrollment in this clinical trial. And company expects to report interim data for the CBeyond™ Phase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period.
    • 23 Sep 2024 According to a Skye Bioscience media release, the company is expected to report interim weight loss data in Q2 2025 and top-line data in Q4 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top